Boston Scientific
Boston Scientific, we work collaboratively to solve healthcare’s toughest problems by developing solutions that matter most to those suffering from debilitating.
Launch date
Employees
Market cap
€112.2b
Enterprise valuation
€119.5b (Public information from Sep 2024)
Share price
$82.57 BSX
Marlborough Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 9.9b | 11.9b | 12.7b | 14.2b | 16.3b | 18.0b | 19.8b |
% growth | (8 %) | 20 % | 7 % | 12 % | 14 % | 11 % | 10 % |
EBITDA | 1.8b | 2.8b | 2.8b | 3.6b | 4.8b | 5.4b | 6.1b |
% EBITDA margin | 18 % | 23 % | 22 % | 25 % | 29 % | 30 % | 31 % |
Profit | (140m) | 1.0b | 698m | 1.6b | 2.1b | 2.8b | 3.3b |
% profit margin | (1 %) | 9 % | 6 % | 11 % | 13 % | 15 % | 17 % |
EV / revenue | 5.9x | 5.7x | 5.9x | 6.5x | 7.8x | 6.9x | 6.1x |
EV / EBITDA | 32.1x | 24.3x | 26.5x | 25.7x | 26.5x | 22.8x | 19.7x |
R&D budget | 1.1b | 1.2b | 1.3b | 1.4b | - | - | - |
R&D % of revenue | 12 % | 10 % | 10 % | 10 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
* | N/A | $1.0b | Post IPO Debt |
* | N/A | $2.0b | Post IPO Equity |
* | N/A | €3.0b | Post IPO Debt |
* | $9.1m | Post IPO Equity | |
* | $18.8m | Post IPO Equity | |
* | N/A | $2.0b | Post IPO Debt |
Total Funding | - |
Related Content
Recent News about Boston Scientific
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by Boston Scientific Jul 2018
ACQUISITION by Boston Scientific Jan 2011
ACQUISITION by Boston Scientific Jan 2011
ACQUISITION by Boston Scientific Nov 2016
ACQUISITION by Boston Scientific May 2019
ACQUISITION Feb 2015
ACQUISITION by Boston Scientific Aug 2018